참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Phosphate Buffered Saline | HCID 24978514 | — |
| 반응물 | citrate Tris | HCID 92017416 | — |
| 생성물 | Squalene | HCID 638072 | — |
반응 단계
10 Baboons were divided into two groups (five baboons per group) and administered the formulations specified in Table 1. For Group 1, equal parts of the adjuvant MF59-0, and p24gag/sf2 (in a citrate/Tris buffer) were combined to yield a total of 0.7 ml. The composition was gently mixed and 500 μl (to yield 100 μg p24gag/sf2/dose) of vaccine was injected intramuscularly (IM) in the thigh muscle. For Group 2, 1.5 ml of 2× phosphate buffered saline (PBS) was added to 46.8 mg of the PLG-entrapped p24gag/sf2 formulation produced in Example 1. The material was vortexed for about 30 seconds until all beads were in suspension. 1.5 ml of MF59-0 was added to the resuspended beads to yield a total of 3 ml. The composition was gently mixed and 500 μl (to yield 100 μg p24gag/sf2/dose) of vaccine was injected IM in the thigh muscle.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US06855492B2 |
|---|
| 출처 데이터셋 | uspto-grants-2005_02 |
|---|
| ORD ID | ord-324879adf1fa4d478af0321942615a58 |
|---|
| 출처 메모 | uspto-grants-2005_02 |
|---|